RT Journal Article
T1 Direct‐acting antivirals are effective and safe in HCV/ HIV‐coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study
A1 Manzardo, Christian
A1 Calvo Pulido, Jorge
A1 Miro, Jose M.
AB Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.
PB Elsevier
SN 1600-6135
YR 2018
FD 2018-06-22
LK https://hdl.handle.net/20.500.14352/115278
UL https://hdl.handle.net/20.500.14352/115278
LA eng
NO Manzardo C, Londoño MC, Castells L, et al. Direct‐acting antivirals are effective and safe in HCV/HIV‐coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am J Transplant. 2018;00:1–10. https://doi.org/10.1111/ajt.14996
NO La Fundación para la Investigación y la Prevención del Sida en España
NO Ministerio de Sanidad (España)
DS Docta Complutense
RD 7 abr 2025